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When conventional treatments of malignant pleural
effusion, such as repeated thoracentesis, closed thoracotomy
and pleurodesis by instilled sclerosing agents, are ineffective,
there are few alternative therapies available. Our case involves
a 47-year-old woman with uterine cervical carcinoma suffering
from malignant pleural effusion. She presented with a chief
complaint of severe dyspnea, and was classified as an Eastern
Cooperative Oncology Group (ECOG) performance status of
4. Her underlying cervical carcinoma progressed despite vari-
ous systemic chemotherapy regimens. In addition, pleural
effusion persisted in spite of 4 weeks of drainage through the
thoracotomy tube and talc pleurodesis. Under such circum-
stances, we attempted intrapleural chemotherapy with cisplatin
plus cytarabine, which resulted in significant decrease of the
pleural effusion. No serious systemic toxicities, including
myelosuppression, were observed. As a result, the patient's
dyspnea was relieved, and her ECOG performance status
improved from 4 to 2. However, the thoracotomy tube was not
removed due to subsequent iatrogenic pneumothorax. Pleural
effusion did not recur for the 4 weeks leading up to her death.
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INTRODUCTION
Malignant pleural effusion (MPE) occurs fre-
quently in patients with advanced malignancies,
and is associated with a short life expectancy and
may cause considerable morbidity.
1 Most effu-
sions do not respond to systemic chemotherapy,
thus treatment is generally palliative. Conven-
tional treatments of MPE include repeated thora-
centesis, closed thoracotomy, pleurodesis (whose
effect results from inflammation secondary to
sclerosing agents), intrapleural chemotherapy
with cytotoxic chemotherapeutic agents, and
pleurectomy for palliation of symptoms or control
of overall disease course.
1 Of these treatments,
talcation is now the treatment of choice for MPE,
with all other therapies considered as alterna-
tives.
1 However, effective alternative treatment
was not established for refractory MPE. Parti-
cularly, if the patient's general condition was
poor, medical teams are apt to evaluate these
patients without any viable treatment options to
formulate a plan. We attempted to treat precisely
this type of MPE patient with intrapleural
cisplatin plus cytarabine. This treatment was
selected based on known effectiveness and safety
of intrapleural chemotherapy in patients with
previously untreated MPE from various kinds of
carcinomas.
CASE REPORT
In February of 2004, a 47-year-old woman with
underlying uterine cervix carcinoma was admitted
to our hospital with a 3 week history of severe
dyspnea. She was diagnosed with uterine cervical
adenocarcinoma (stage IIb) in March of 2000. The
patient had undergone concurrent chemoradiation
therapy with 5-FU/cisplatin and achieved complete
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remission. Multiple lung metastases occurred in
November of 2001, and she received the 2nd line
chemotherapy with paclitaxel/ifosfamide, the 3rd
line chemotherapy with etoposide, and the 4th
line chemotherapy with BVM (bleomycin,
vincristine, mitomycin-C) regimens. However, the
lung metastases progressed, and brain metastases
developed newly after 2 cycles of BVM chemo-
therapy in January of 2003. No further systemic
chemotherapy was performed.
The patient looked acutely ill on presentation,
and was tachypneic (30/min). All other vital signs
were within normal limits. Her Eastern Coopera-
tive Oncology Group (ECOG) performance status
was 4. No jugular venous distention was appre-
ciated on physical exam. Breathing sounds
decreased in the left upper lung field, with
dullness on percussion. Chest CT scan (Fig. 1) and
chest x-ray (Fig. 2) revealed a large amount of left
pleural effusion and multiple lung metastases.
Aside from a moderate hyponatremia (128 mEq/
L), the complete blood cell count and serum
chemistries were within normal limits. Liver and
renal functions were normal. Cytology report of
the pleural effusion revealed adenocarcinoma,
suggesting a malignant pleural effusion secondary
to uterine cervical cancer.
Closed thoracotomy was performed on the day
after admission. 1,450 mL of pleural fluid was
drained through the thoracotomy tube on day
one. A daily median amount of 320 mL (range,
110 - 440) was drained for 25 days consecutively.
Because at that time, the patient refused any
further invasive treatments, delayed pleurodesis
with 2.0 g of talc slurry was performed on day 26
of thoracotomy. However, pleural effusion did not
decrease (Fig. 3).
After the patient gave written informed consent,
she received intrapleural chemotherapy on day 32
of thoracotomy with cisplatin 100 mg/m
2 and
cytarabine 1,200 mg/m
2 mixed into 250 mL
normal saline. The patient was given pretreatment
hydration with 2 L of normal saline and furose-
mide. She also received premedication 30 minutes
prior to cisplatin chemotherapy, including IV
infusion of granisetron (3 mg) and dexamethasone
(10 mg). The mixed chemotherapeutic agents were
infused through the thoracotomy tube, and a
change in position was performed every 15 to 20
minutes. The instilled drugs were drained 4 hours
later.
Since day 2 of intrapleural chemotherapy, daily
drainage of pleural fluid decreased dramatically
to a median amount of 110 mL (range, 20 - 240)
until day 18 of intrapleural chemotherapy. Its
daily drainage further decreased to less than 100
mL over the last 6 days (Fig. 4). This minimal
Fig. 2. At the time of admission. Huge amount of pleural
effusion in the left lung and the deviation of the heart and
the trachea were noted.
Fig. 1. Chest CT scan performed on admission. Large
amount of pleural effusion in the left lung and multiple
lung metastases were observed.
Fig. 3. After pleurodesis. A small decrease of pleural
effusion in the left lung was seen. On hospital day 26,
even pleurodesis with 2.0 g talc was not significantly
effective.Intrapleural Cisplatin/Cytarabine in an Intractable Case
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pleural fluid reaccumulation was equivalent to
partial response, defined as 75% or greater
reduction of pleural effusion compared to baseline
pretreatment chest radiograph, as noted in a pre-
vious, intrapleural chemotherapy trial.
2 Toxicity
consisted of grade 1 nausea and grade 2 pleuritic
chest pain according to the National Cancer
Institute's Common Toxicity Criteria version 3.0.
3
No myelosuppression was observed.
We were unable to remove thoracotomy tube
due to iatrogenic pneumothorax, which developed
during exchange of the subclavian catheter on day
9 of intrapleural chemotherapy. However, her
dyspnea due to malignant pleural effusion was
relieved significantly due to intrapleural chemo-
therapy. ECOG performance status was improved
from 4 to 2. Pleural effusion did not recur for the
4 weeks leading up to her death.
DISCUSSION
Systemic chemotherapy is generally disappointing
for the control of malignant pleural effusions.
When the underlying malignancy is chemo-sensi-
tive, systemic chemotherapy might be the treatment
of choice for malignant pleural effusion. Otherwise,
tube thoracotomy with subsequent pleurodesis
has traditionally been recommended.
1 A number
of sclerosing agents, such as tetracycline, bleomycin,
and talc, were used for MPE.
1 Talc is now the
standard agent for sclerosing the pleural space in
patients with malignant pleural effusions
although fever is a relatively common adverse
effect.
1
In contrast to traditional sclerosing agents,
intrapleural chemotherapy has the potential
advantage of treating the underlying malignancy
in addition to providing local control of MPE.
2





and cisplatin plus cytarabine.
2,7,8 Cisplatin has
been widely used as an agent for intracavitary
chemotherapy and has been shown to be safe and
effective.
9
On the basis of in vitro results demonstrating
cisplatin and cytarabine were synergistic,
10
Markman et al. conducted phase I and II studies
of intrapleural chemotherapy with cisplatin plus
cytarabine.
7 Subsequently, in 1994 the Lung
Cancer Study Group evaluated the effectiveness of
intrapleural cisplatin plus cytarabine in patients
with previously untreated MPE from various
malignancies, such as lung, breast, ovarian, pleu-
ral, esophageal, pancreas, and stomach cancers,
resulting in good response.
2 Guided by these
studies, we administered intrapleural chemo-
therapy in a uterine cervical cancer patient with
refractory MPE. Intrapleural chemotherapy with
palliative aim had not been previously tested in
this type of patient. We observed this regimen, in
a heavily-treated and exhausted patient, which
resulted in a dramatic decrease of pleural effusion
and subsequently in relief of patient symptoms.
Although we did not evaluate pharmacokinetics
in this case, previous studies suggest intracavitary
chemotherapy can lead to higher intracavitary
concentration of drugs than systemic chemo-
therapy,
11,12 which might induce good response.
Cisplatin had been effective in this patient when
she was first diagnosed with uterine cervical
cancer, and readministration of this active agent
might contribute to a good response. Otherwise,
successful response in this case might be due to
synergistic, cytotoxic effect of the two drugs.
10
In conclusion, intrapleural chemotherapy with
cisplatin plus cytarabine can be considered as
palliative treatment for intractable malignant
pleural effusion, particularly if the patient has a
poor performance status and has no other
available options.
Fig. 4. After intrapleural chemotherapy. Pleural effusion
in the left lung greatly decreased and left lung reex-
panded fully. On day 11 of intrapleural chemotherapy
with cisplatin plus cytarabine, the median amount of
drained fluid decreased to 110 mL.Yong Wha Moon, et al.
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